ArticleBiology direct2026
LDN-57444 sensitizes hepatocellular carcinoma cells to sorafenib by promoting ferroptosis through histone deacetylase 2 (HDAC2) inhibition.
Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) is still one of the leading causes of cancer-related mortality worldwide. Sorafenib is commonly used as first-line systemic treatment for advanced HCC, but the clinical benefits fall victim to either primary or acquired drug resistance. Modulating ferroptosis, a form of iron-dependent regulated cell death (RCD), has been increasingly explored in order to circumvent this chemoresistance.
methodsWe performed a pharmacogenomic screening analysis using the DepMap database to identify small molecules whose cytotoxicity patterns resemble those of known ferroptosis inducers. Among the candidates, LDN-57444 was selected for further evaluation. Its ability to enhance the anticancer activity of sorafenib was examined in PLC/PRF/5 and Hep3B HCC cell lines using cell viability assays, molecular docking, cellular thermal shift assays (CETSA), and siRNA-mediated gene silencing.
resultsIn the HCC models tested, sorafenib alone did not induce ferroptosis, unlike some earlier reports. LDN-57444, previously described as an inhibitor of ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1), emerged as a strong ferroptosis sensitizer. Co-treatment with LDN-57444 and sorafenib led to pronounced synergistic cytotoxicity, and this effect was completely abolished by the ferroptosis inhibitor ferrostatin-1. Mechanistic analyses showed that the synergy is independent of UCH-L1. Structural modeling and target-engagement experiments indicated that histone deacetylase 2 (HDAC2) is the relevant molecular target. Silencing HDAC2, but not HDAC1, reduced sensitivity to the drug combination, supporting the idea that LDN-57444 enhances sorafenib activity by modulating HDAC2.
conclusionOur findings demonstrate that LDN-57444 potentiates sorafenib-induced ferroptosis in HCC cells through an HDAC2-dependent mechanism. These results highlight the therapeutic potential of combining HDAC2 inhibitors with sorafenib to improve treatment responses in advanced HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.